Fresenius Medical Care stock (DE0005785802): UBS keeps Sell view as Xetra trade steadies

Fresenius Medical Care shares traded at EUR 37.92 on Xetra on 05/26/2026, while UBS kept its Sell rating and EUR 37 price target on 06/01/2026.

Fresenius Medical Care shares were last quoted at EUR 37.92 on Xetra on 05/26/2026, according to comdirect, as the Frankfurt-listed dialysis group remained in focus on the German market. On 06/01/2026, UBS reiterated a Sell stance with a EUR 37 price target, leaving the home-country debate centered on valuation and the company's operating outlook in Germany's large-cap healthcare space.

The stock's latest print was still above UBS's target, and the comparison matters because the share price and the bank view were both dated this week. For investors tracking the DAX-linked healthcare name, the key reference points remain the Xetra quotation and the latest Swiss research note, which frames sentiment around earnings durability rather than a fresh corporate event. See the share data at comdirect as of 05/26/2026 and the analyst note at finanzen.net as of 06/01/2026.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: FMC
• Sector/industry: Healthcare services, dialysis care and renal products
• Headquarters/country: Bad Homburg, Germany
• Core markets: Europe, North America and other international markets
• Key revenue drivers: Dialysis treatments, clinical services and related renal-care products
• Home exchange/listing venue: Xetra (FME) - German listing optional
• Trading currency: EUR

Fresenius Medical Care: core business model

Fresenius Medical Care runs a global kidney-care platform that combines dialysis treatment centers with products used in renal therapy, giving the company a mix of service revenue and equipment-related sales.

Recent corporate actions

No completed delisting or take-private was identified in the supplied dated sources, so the share remains treated as actively listed on Xetra. The most recent public market datapoint in the search set was the Xetra quote and UBS's same-day research view, both pointing to normal trading rather than any transaction close.

What banks and research houses say about Fresenius Medical Care

UBS kept its Sell rating and EUR 37 target on 06/01/2026, according to the dpa-AFX-distributed note carried by finanzen.net. The same source said the bank pointed to upcoming data for a competing product, underscoring that near-term sentiment is still tied to operating evidence rather than a new strategic announcement.

Conclusion

The stock enters the week with a clear German-market reference point: Xetra pricing at EUR 37.92 and a fresh UBS Sell call at EUR 37.00. With no new corporate action in the dated source set, the day's focus stays on how the market weighs that valuation gap against operating visibility.

The Monday analyst module adds a second layer of context by showing that one major bank remains cautious. That makes the share-price relationship to research coverage the main narrative rather than any takeover or restructuring angle.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.